TrialLeukemia & lymphoma2023

Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with

David Qualls et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.